VALENTINI, Gabriele
VALENTINI, Gabriele
Dipartimento di Medicina di Precisione
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity.
2012 Cappelli, S; Bellando Randone, S; Martinović, D; Tamas, Mm; Pasalić, K; Allanore, Y; Mosca, M; Talarico, R; Opris, D; Kiss, Cg; Tausche, Ak; Cardarelli, S; Riccieri, V; Koneva, O; Cuomo, Giovanna; Becker, Mo; Sulli, A; Guiducci, S; Radić, M; Bombardieri, S; Aringer, M; Cozzi, F; Valesini, G; Ananyeva, L; Valentini, Gabriele; Riemekasten, G; Cutolo, M; Ionescu, R; Czirják, L; Damjanov, N; Rednic, S; Matucci Cerinic, M.
-238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis
2005 Tolusso, B; Fabris, M; Caporali, R; Cuomo, Giovanna; Isola, M; Soldano, F; Montecucco, C; Valentini, Gabriele; Ferraccioli, G.
.ANTI-TNF alfa IN PATIENTS WITH EITHER RHEUMATOID ARTHRITIS OR SPONYLOATHRITIS And CONCURRENT C HEPATITIS:A RETROSPECTIVE RECORD REVIEW ON SAFETY
2010 Tirri, Rosella; Monaco, M. G. L.; Orefice, M; Valentini, Gabriele
.Spectrum of cardiac involvement in systemic lupus erythematosus: echocardiographic, echo-Doppler observations and immunological investigation.
1993 Giunta, A; Picillo, U; Maione, S; Migliaresi, S; Valentini, Gabriele; Arnese, M; Losardo, L; Marone, M; Tirri, G; Condorelli, M.
2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative
2013 Van Den Hoogen, Frank; Khanna, Dinesh; Fransen, Jaap; Johnson, Sindhu R.; Baron, Murray; Tyndall, Alan; Matucci-Cerinic, Marco; Naden, Raymond P.; Medsger Jr., Thomas A.; Carreira, Patricia E.; Riemekasten, Gabriela; Clements, Philip J.; Denton, Christopher P.; Distler, Oliver; Allanore, Yannick; Furst, Daniel E.; Gabrielli, Armando; Mayes, Maureen D.; Van Laar, Jacob M.; Seibold, James R.; Czirjak, Laszlo; Steen, Virginia D.; Inanc, Murat; Kowal-Bielecka, Otylia; Müller-Ladner, Ulf; Valentini, Gabriele; Veale, Douglas J.; Vonk, Madelon C.; Walker, Ulrich A.; Chung, Lorinda; Collier, David H.; Csuka, Mary Ellen; Fessler, Barri J.; Guiducci, Serena; Herrick, Ariane; Hsu, Vivien M.; Jimenez, Sergio; Kahaleh, Bashar; Merkel, Peter A.; Sierakowski, Stanislav; Silver, Richard M.; Simms, Robert W.; Varga, John; Pope, Janet E.
[A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens].
2006 Cuomo, Giovanna; Molinaro, G; La Montagna, G; Migliaresi, S; Valentini, Gabriele
[Absolute and relative increase in Leu-11b+ cells in patients with systemic scleroderma]
1984 Valentini, Gabriele; Chianese, U; Gualdieri, L; Maniera, A; Giordano, M.
[Atherosclerosis and rheumatoid arthritis: relationships between intima-media thickness of the common carotid arteries and disease activity and disability].
2004 Cuomo, Giovanna; Di Micco, P; Niglio, A; La Montagna, G; Valentini, Gabriele
[Cardiopathy in systemic sclerosis]
1996 Valentini, Gabriele; Maione, S.
[Comparison between auranofin and chloroquine in the therapy of rheumatoid arthritis]
1986 Gallo, M; LA MONTAGNA, Giovanni; Valentini, Gabriele
[Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
2009 Bombardieri, S; Ferraccioli, G; Ferri, C; Galeazzi, M; Lapadula, G; Cerinic, Mm; Montecucco, C; Triolo, G; Trotta, F; Valentini, Gabriele
[Early systemic sclerosis: diagnostic criteria and work-up].
2002 Valentini, Gabriele
[Eosinophilic fasciitis. A recently reported oligotopic connective tissue inflammation. A case report]
1980 Giordano, M; Ara, M; Rossiello, Raffaele; Cicala, C; Valentini, Gabriele
[Epidemiology and risk factors in osteoarthritis: literature review data from "OASIS" study].
2004 De Filippis, L; Gulli, S; Caliri, A; Romano, C; Munaò, F; Trimarchi, G; La Torre, D; Fichera, C; Pappalardo, A; Triolo, G; Gallo, M; Valentini, Gabriele; Bagnato, G; Gruppo, Oasis
[FRI0313] CYCLOPHOSPHAMIDE PULSE THERAPY IN THE TREATMENT OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE G. Abignano, M. Iudici, A. Petrillo, G. Cuomo, G. Valentini. Rheumatology Unit, Second University of Naples, Napoli, Italy Background: Cyclophosphamide (CYC) is currently used in the treatment of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). A recent meta-analysis1 (Nannini C et al), pooling data from studies based on different entry criteria, questions its usefulness. Objectives: To investigate the effectiveness of low dose pulse CYC (500 mg/dose) in the treatment of recently deteriorating SSc-ILD. Methods: 51 patients with SSc-ILD, all of them satisfying ACR criteria for the classification of the disease and presenting with a recent (<6 months) decrease (≥10% of the predictive value) of either Forced Vital Capacity (FVC) or Diffusing Lung Capacity for CO (DLCO), were enrolled in the study. All of them underwent a concurrent prednisone therapy (10 mg/daily). CYC was administered i.v. at a dose of 500 mg weekly. Total CYC dose ranged from 4.5 to 11.5 g (median 7.5). An increase of 10% in either FVC or DLCO was considered indicative of improvement; a change between <10% and >10% of stable disease; a decrease ≥10% of worsening. Results: 22 out of the 51 SSc patients (43.14%) resulted to improve at the end of the CYC course; 17 (33.33%) remained stable; 12 (23.53%) worsened. No patients withdrew CYC treatment because of side effects. Conclusion: Our study suggests that the effectiveness of CYC in SSc-ILD may depend on entry criteria. Actually about 76% of patients who had experienced a recent deterioration of lung function, suggesting active alveolitis, underwent improvement or stabilization of their disease in our study. References:[ol][li]Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008, 10:R124.[/li][/ol]Disclosure of Interest: None declared Ann Rheum Dis 2009;68(Suppl3):460 Session: Scleroderma, myositis and related syndromes
2009 Abignano, G.; Iudici, M.; Petrillo, A.; Cuomo, Giovanna; Valentini, Gabriele
[HAQ-DI Italian version in systemic sclerosis].
2006 La Montagna, G; Cuomo, Giovanna; Chiarolanza, I; Ruocco, L; Valentini, Gabriele
[Hypocomplementemia in systemic sclerosis].
2008 Cuomo, Giovanna; Abignano, G; Ruocco, L; Vettori, Serena; Valentini, Gabriele
[Italian consensus on the recommendations about the use of methotrexate for the treatment of rheumatic diseases with a focus on rheumatoid arthritis: results from the "3E initiative"].
2010 De Leonardis, F; Alivernini, S; Bonacci, E; Buono, Am; Bombardieri, S; Ferraccioli, Gf; Montecucco, C; Sinigaglia, L; Trotta, F; Valentini, Gabriele
[Metabolic syndrome in inflammatory rheumatic diseases].
2006 Malesci, D; Valentini, Gabriele; La Montagna, G.
[Rarity of sclerodermic renal crisis in the Italian population and the uncommon nature of the Vogt-Koyanagi-Harada syndrome in systemic sclerosis]
1986 Giordano, M; LA MONTAGNA, G; Capelli, L; Vatti, M; Valentini, Gabriele